Get the Stockscreener App
75.65
1.12%
0.84
Pre-market:
75.73
0.08
+0.11%
Zoetis Inc stock is traded at $75.65, with a volume of 4.09M.
It is up +1.12% in the last 24 hours and up +3.67% over the past month.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
See More
Previous Close:
$74.81
Open:
$75
24h Volume:
4.09M
Relative Volume:
0.95
Market Cap:
$31.26B
Revenue:
$9.51B
Net Income/Loss:
$2.64B
P/E Ratio:
12.53
EPS:
6.0361
Net Cash Flow:
$2.14B
1W Performance:
+6.06%
1M Performance:
+3.67%
6M Performance:
-37.00%
1Y Performance:
-46.82%
1-Day Range:
$0.00
$0.00
1-Week Range:
$71.11
$75.69
52-Week Range:
$68.77
$148.30
Zoetis Inc Stock (ZTS) Company Profile
Compare ZTS vs TAK, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZTS
Zoetis Inc
|
75.65 | 31.26B | 9.51B | 2.64B | 2.14B | 6.0361 |
TAK
Takeda Pharmaceutical Co Adr
|
18.68 | 59.67B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.17 | 48.02B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.50 | 41.78B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
550.10 | 23.59B | 3.17B | 1.29B | 1.01B | 27.09 |
Zoetis Inc Stock (ZTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-27-26 | Downgrade | Argus | Buy → Hold |
| Apr-15-26 | Initiated | Citigroup | Buy |
| Jan-22-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-17-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-18-25 | Downgrade | Stifel | Buy → Hold |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-12-24 | Reiterated | Stifel | Buy |
| Dec-19-23 | Resumed | Jefferies | Buy |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-08-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-08-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-21-20 | Initiated | Atlantic Equities | Overweight |
| Aug-14-20 | Upgrade | Edward Jones | Hold → Buy |
| Aug-12-20 | Downgrade | Gabelli & Co | Buy → Hold |
| May-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Sep-09-19 | Initiated | Goldman | Buy |
| Jul-01-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-23-19 | Initiated | Guggenheim | Buy |
| May-03-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Mar-04-19 | Upgrade | Stifel | Hold → Buy |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-15-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-22-18 | Downgrade | Stifel | Buy → Hold |
| Aug-03-18 | Reiterated | Stifel | Buy |
| Apr-19-18 | Reiterated | Citigroup | Buy |
| Mar-19-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-16-18 | Reiterated | Stifel | Buy |
| Jan-04-18 | Upgrade | Citigroup | Neutral → Buy |
View All
Zoetis Inc Stock (ZTS) Latest News
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know - Zacks Investment Research
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Zoetis' Simparica Trio Shows Superior Heartworm Protection; ZTS Dividend Remains Attractive - GuruFocus
Zoetis Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Zoetis Inc. stock outperforms competitors on strong trading day - MarketWatch
Zoetis Inc. stock outperforms competitors on strong trading day - MarketWatch
Zoetis (CEUX:ZOED) Change In Prepaid Assets : €0.00 Mil (TTM As of Jun. 2026) - GuruFocus
Vietnam Veterinary Vaccine Import Market and Top 10 Importers Guide 2023-2026 | Import Reliance and Aquaculture Growth Create Market Entry Opportunities - GlobeNewswire Inc.
Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack? - Yahoo Finance
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Zoetis Inc. stock underperforms Thursday when compared to competitors - marketwatch.com
US98978VAX1 Bond Profile: Coupon and Redemption - TradingView
Zoetis stock hits 52-week low at $69.48 - Investing.com
Join Class Action to Recover Losses from Zoetis Inc. (ZTS) – Contact Levi & Korsinsky Before July 27, 2026 - ACCESS Newswire
PFE4666688 Bond Profile: Coupon and Redemption - TradingView
Zoetis shares drop 71% since 2021 but remain a buy with strong margins and pipeline potential. - Pluang
Zoetis: Priced For The Worst, Worth Buying (NYSE:ZTS) - Seeking Alpha
Zoetis Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Zoetis Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
PFE4538720 Bond Profile: Coupon and Redemption - TradingView
Zoetis Adds Equine Hematology Capabilities to Vetscan OptiCell and Vetscan Imagyst - myvetcandy.com
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
Zoetis Inc. stock outperforms competitors on strong trading day - MarketWatch
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Zoetis Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results - Business Wire
Zoetis Inc. stock outperforms competitors despite losses on the day - MarketWatch
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales - Yahoo Finance
Michael Burry Sells FLUT To Pile Into LULU Under $100 — Plus A New Bet On ZTS - TradingView
Why Are Zoetis (NYSE:ZTS) Diagnostics in S&P 500 Focus? - Kalkine Media
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? - Yahoo Finance
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? - Trefis
Zoetis Shares Slide Following Earnings RevisionEarnings Deceleration Risk - vinanet.vn
Zoetis Stock (ZTS) Opinions on Michael Burry Portfolio Update - Moomoo
Zoetis Stock (ZTS) Opinions on Michael Burry Portfolio Update - Quiver Quantitative
Zoetis Taps Former GE HealthCare CFO Jay Saccaro as CFO and COO - The Healthcare Technology Report.
Zoetis Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Paws and profits: Zoetis appoints global diagnostics president, NVA names chief medical officer, and more updates - DVM360
Zoetis (ZTS) Shares Drop After Earnings Revision - Yahoo Finance
Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030 - GlobeNewswire Inc.
Zoetis Inc. (ZTS) Investor Outlook: Unlocking a 26.63% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Is Zoetis Stock Underperforming the S&P 500? - Yahoo Finance
Zoetis Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - BioSpace
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Business Wire
Zoetis (NYSE:ZTS) Offers Value and Quality in One Attractive Package - ChartMill
Zoetis Inc. (ZTS) - DirectorsTalk Interviews
Zoetis Inc. stock outperforms competitors on strong trading day - MarketWatch
Zoetis Inc Stock (ZTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zoetis Inc Stock (ZTS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bisaro Paul | Director |
May 13 '26 |
Buy |
75.88 |
2,000 |
151,750 |
27,862 |
| MCCALLISTER MICHAEL B | Director |
May 11 '26 |
Buy |
77.76 |
3,000 |
233,273 |
24,524 |
| PECK KRISTIN C | Chief Executive Officer |
Feb 17 '26 |
Option Exercise |
41.83 |
20,000 |
836,600 |
121,337 |
| PECK KRISTIN C | Chief Executive Officer |
Feb 17 '26 |
Sale |
127.05 |
20,000 |
2,540,964 |
101,337 |
| Polzer Robert J | Officer |
Feb 17 '26 |
Proposed Sale |
127.34 |
2,346 |
298,742 |
0 |
| PECK KRISTIN C | Officer |
Feb 17 '26 |
Proposed Sale |
127.05 |
20,000 |
2,540,964 |
0 |
| Polzer Robert J | Officer |
Feb 13 '26 |
Proposed Sale |
129.09 |
3,662 |
472,728 |
0 |
0.17%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):